NQO1*2 [NAD(P)H: Quinone oxidoreductase 1] polymorphism and its influence on acute leukemia risk

Biology and Medicine

Volumn 3, Issue 3, 2011, Pages 19-25

  Dunna, N R ^a   Anuradha, C ^a   Vure, S ^a   Sailaja, K ^a   Surekha, D ^a   Raghunadharao, D ^b   Rajappa, S ^b   Vishnupriya, S ^a  

^a OSMANIA UNIVERSITY   (India)

^b NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

ALL; AML; DFS; NQO1*2; Polymorphism

Indexed keywords

EID: 84861965100     PISSN: None     EISSN: 09748369     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Benson AM, 1980. Increase of NAD(P)H:quinone reductase by dietary antioxidants: possible role in protection against carcinogenesis and toxicity. Proceedings of National Academy of Sciences USA, 77: 5216-5220.
2. Kelsey KT, 1997. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. British Journal of Cancer, 76: 852-854.
3. Kracht T, 2004. NQO1 C609T polymorphism in distinct entities of pediatric hematologic neoplasms. Haematologica. 89:1492-7.
4. Krajinovic M, 2002. Role of NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. International Journal of Cancer, 97(2): 230-236.
5. Krajinovic M, 2005. Further insight into the role of NQO1 in childhood leukemia. Haematologica, 90: 1445.
6. Lahiri DK, 1991. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Research, 19: 5444.
7. Larson RA, 1999. Prevalence of the inactivating 609CT polymorphism in the NAD(P)H: quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood, 94: 803-807.
8. Naoe T, 2000. Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related Leukemia/Myelodysplastic Syndrome and de novo Acute Myeloid Leukemia. Clinical Cancer Research, 6: 4091-4095.
9. Ross D, 2004. NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. Methods in Enzymology, 382: 115-44.
10. Rosvold EA, 1995. Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics, 5: 199-206.
11. Rothman N, 1997. Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609C→T mutation and rapid fractional excretion of chlorzoxazone. Cancer Research, 57: 2839-2842.
12. Siegel D, 1999. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics, 9: 113-21.
13. Sirma S, 2004. NAD(P)H:quinone oxidoreductase 1 null genotype is not associated with pediatric de novo acute leukemia. Pediatric Blood Cancer, 43: 568-70.
14. Smith MT, 2001. Low NAD(P)H:quinone oxidoreductase 1 activity is associated with increased risk of acute leukemia in adults. Blood, 97: 1422-1426.
15. Smith MT, 2002. Low NAD(P)H:quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children. Blood, 100: 4590-3.
16. Waleh NS, 1998. The redox-sensitive human antioxidant responsive element induces gene expression under low oxygen conditions. Carcinogenesis, 19: 1333-1337.
17. Wiemels JL, 1999. United Kingdom Childhood Cancer Study Investigators. A lack of a functional NAD(P)H: quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. Cancer Research, 59: 4095-4099.
18. Winski SL, 2002. Subcellular localization of NAD(P)H: quinone oxidoreductase 1 in human cancer cells. Cancer Research, 62: 1420-1424.